Podcast Episode 10: What The Expanded CMS Guidelines Mean for your Medicare Patients

OlgaDalisay — Tue, 16 May 2023 17:54:00 +0000

05/16/2023

OlgaDalisay Tue, 05/16/2023 - 17:54

Guest Speakers: Jesse Bushman, Director, Market Access, and Renee Taylor MS, RD, BC-ADM, CDCES, Director, Medical Science at Dexcom

Real-time real talk is intended for healthcare professionals in the US.

In this episode of Real-Time Real Talk our host, Cher Pastore MS, RD, CDCES, BC-ADM, is joined by Jesse Bushman, Director, Market Access, and Renee Taylor MS, RD, BC-ADM, CDCES, Director, Medical Science at Dexcom to discuss the recent update from Centers of Medicare & Medicaid Services (CMS) regarding the expanded guidelines for Continuous Glucose Monitoring (CGM) coverage.

Renee Taylor MS, RD, BC-ADM, CDCES	Jesse Bushman

Our guests will go into detail about the new coverage criteria and what it means for people with Type 2 diabetes. They will explain the clinical evidence¹ that enabled this change, and how CGM predictive alerts can help minimize the risk of diabetes complications, including severe hypoglycemia².

About expanded Medicare guidelines

Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444
Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 May;16(3):677-682. doi: 10.1177/1932296820982584. Epub 2021 Jan 5. PMID: 33401946; PMCID: PMC9294577.

Podcast

Clinical Evidence - Type 2 Diabetes

Clinical Evidence - Data Interpretation

Clinical Evidence

Coverage & Reimbursement

Podcasts

Yes

Related Resources

Podcast Episode 21: Clinical Accuracy in CGM and Why It Matters

Premium Content

Off